Chemically modified tetracyclines show activity in mammalian cell pathways and diseases related to cancer, inflammation, and neurodegenerative pathways. 4-Dedimethylaminosancycline (CMT-3 or COL-3) acts as matrix metalloproteinase (MT-MMP) inhibitor. It has been studied in disorders of collagen destruction, excessive TNF activity, excessive nitric oxide activity, excessive IL-1 activity, excessiuve activity of elastase, bone loss, protein degradation, muscle wasting, collagen glycosylation, phospholipase A2 activity. In addition, CMT-3 has been investigated for the treatment of aneurysms, ulcerations, periodontal disease, diabetes, scleroderma, progeria, cancer, and diseases of bone marrow function and thrombocytopenia.
1) Nip, L H, Uitto, V J, Golub, L M, “Inhibition of epithelial cell matrix metalloproteinases by tetracyclines” J. Periodontal Research, 1993, 28(5), 379-85. DOI:10.1111/j.1600-0765.1993.tb01082
2) Sasaki, T, Kaneko, H, Ramamurthy, N S, Golub, L M, “Tetracycline administration restores osteoblast structure and function during experimental diabetes” Anatomical Record, 1991, 231(1), 25-34. DOI:10.1002/ar.1092310105.
3) Schneider, B S, Maimon, J, Golub, L M, Ramamurthy, N S, Greenwald, R A, “Tetracyclines inhibit intracellular muscle proteolysis in vitro” Biochemical and Biophysical Research Communications, 1992, 188(2), 767-72 DOI:10.1016/0006-291X(92)91122-7.
4) Seftor, R E B, Seftor, E A, De Larco, J E, Kleiner, D E, Leferson, J, Stetler-Stevenson, W G, McNamara, T F, Golub, L M, Hendrix, M J C, “Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis” Clinical & Experimental Metastasis, 1998, 16(3), 217-225.
5) Protasoni, M., et al. (2018). “Mitochondria as oncotarget: a comparison between the tetracycline analogs doxycycline and COL-3.” Oncotarget 9(73): 33818-33831.
Keywords: CMT-3, COL-3, COL-3 Compound, Incyclinide, NSC-683551